Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib

NCT00802841 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

191

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Myelogenous Leukemia

Interventions

DRUG: nilotinib
DRUG: imatinib

Sponsor

Novartis Pharmaceuticals